There has been a series of high-profile failures of drugs in clinical trials of acute ischaemic
stroke that were designed to meet criteria necessary for drug regulatory approval. This has …

Background The free-radical–trapping agent NXY-059 showed promise as a
neuroprotectant in the Stroke–Acute Ischemic NXY Treatment I (SAINT I) trial, reducing …

Stroke is a major clinical problem, and acute pharmacological intervention with
neuroprotective agents has so far been unsuccessful. Recently, there has been …

Background NXY-059 is a free-radical–trapping agent that is neuroprotective in animal
models of stroke. We tested whether it would reduce disability in humans after acute …

There is substantial experimental evidence that free radicals are produced in the brain
during ischemia, during reperfusion and during intracranial hemorrhage. Removal of …

Background and Purpose—In animal models of acute ischemic stroke (AIS), the free radical–
trapping agent NXY-059 showed promise as a neuroprotectant. SAINT I and II were …

Background and Purpose—A previous trial (the Clomethiazole Acute Stroke Study)
generated the hypothesis that clomethiazole is effective in patients with a major ischemic …

Background and Purpose—NXY-059 is a free radical-trapping neuroprotectant developed
for use in acute ischemic stroke. To facilitate prompt administration of treatment, potentially …

Background and Purpose—The efficacy and safety of the neuroprotective drug
clomethiazole was tested in a double blind placebo controlled trial in patients with a clinical …

Background The National Institutes of Health Stroke Scale (NIHSS) was created to detect
treatment-related differences in clinical trials and was designed to measure right-and left …